immune system
• intragastrically MERS-CoV incoculated mice show increased mononuclear cell infiltration in the lamina propria of the small intestine and alveolar septa
|
• intragastrically MERS-CoV incoculated mice show an increase in CD3+ lymphocytes
|
• MERS-CoV infected mice show induction of proinflammatory cytokines
|
• brains of MERS-CoV infected mice show perivascular cuffing after 2 dpi
|
• lungs of MERS-CoV infected mice produce patchy consolidation variably composed of cellular inflammation, vascular congestion, and atelectasis
(J:285467)
|
|
• pantoprazole pretreated intragastrically MERS-CoV inoculated mice show prominent pulmonary inflammation 5 days post infection (dpi) while mice show inflammatory infiltration in the lung at 8 dpi without pantoprazole pretreatment
(J:286231)
|
• intragastrically MERS-CoV inoculated mice show marked infiltration of mononuclear cells and lymphocytes in the alveolar septa, indicating interstitial inflammation
|
• mice infected with MERS-CoV
• viral titers are highest in lung tissues at 2dpi and then decline while in the brain, viral titers are undetectable at 2 dpi but then increase at 4 and 6 dpi
(J:285467)
• virus RNA is detected in the lung and brain and lower levels in the spleen, kidney and heart even though no virus was titered from the kidney
(J:285467)
• MERS-CoV is not transmitted from infected transgenic mice to uninfected transgenic mice housed in the same cages
(J:285467)
• mice vaccinated with Venezuelan equine encephalitis replicon particles expressing the MERS-CoV surface S glycoprotein (VPR-S) are completely protected against lethal infection
(J:285467)
• mice pretreated with serum from mice immunized with VPR-S a day before MERS-CoV infection are completely protected against lethal infection and this passive immunization completely prevents spread of infection to the brain
(J:285467)
|
|
• mice inoculated intragastrically with MERS-CoV strain EMC/2012
• mice treated with pantoprazole (to improve viability of MERS-CoV in the stomach) prior to MERS-CoV intragastrical inoculation show more extensive intestinal and lung pathology and greater viral load in the small intestine compared to non-pantoprazole treated mice
(J:286231)
• mice directly injected with MERS-CoV into the stomach (intragastic injection) after a minor laparotomy show elevated viral load in the small intestine, lungs, and brain
(J:286231)
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
(
J:286231
, J:285467
)
• mice infected with the EMC2012 strain of the Middle East respiratory-coronavirus (MERS-CoV) die at 6-7 days post infection
(J:285467)
• mortality of MERS-CoV-infected mice correlates with brain infection
(J:285467)
|
|
• mice inoculated intragastrically with MERS-CoV show partial penetrance of lethal infection
(J:286231)
|
mortality/aging
increased susceptibility to Coronaviridae infection induced morbidity/mortality
(
J:286231
, J:285467
)
• mice infected with the EMC2012 strain of the Middle East respiratory-coronavirus (MERS-CoV) die at 6-7 days post infection
(J:285467)
• mortality of MERS-CoV-infected mice correlates with brain infection
(J:285467)
|
|
• mice inoculated intragastrically with MERS-CoV show partial penetrance of lethal infection
(J:286231)
|
hematopoietic system
• intragastrically MERS-CoV incoculated mice show increased mononuclear cell infiltration in the lamina propria of the small intestine and alveolar septa
|
• intragastrically MERS-CoV incoculated mice show an increase in CD3+ lymphocytes
|
respiratory system
• some lungs of MERS-CoV infected mice show thrombi, with nearby vascular congestion and lesser hemorrhage and necrosis
|
• lungs of MERS-CoV infected mice produce patchy consolidation variably composed of cellular inflammation, vascular congestion, and atelectasis
|
• lungs of some MERS-CoV infected mice show alveolar edema
|
• lungs of MERS-CoV infected mice produce patchy consolidation variably composed of cellular inflammation, vascular congestion, and atelectasis
(J:285467)
|
|
• pantoprazole pretreated intragastrically MERS-CoV inoculated mice show prominent pulmonary inflammation 5 days post infection (dpi) while mice show inflammatory infiltration in the lung at 8 dpi without pantoprazole pretreatment
(J:286231)
|
• intragastrically MERS-CoV inoculated mice show marked infiltration of mononuclear cells and lymphocytes in the alveolar septa, indicating interstitial inflammation
|
atelectasis
(
J:285467
)
• lungs of MERS-CoV infected mice produce patchy consolidation variably composed of cellular inflammation, vascular congestion, and atelectasis
|
cardiovascular system
• some lungs of MERS-CoV infected mice show thrombi, with nearby vascular congestion and lesser hemorrhage and necrosis
|
• lungs of MERS-CoV infected mice produce patchy consolidation variably composed of cellular inflammation, vascular congestion, and atelectasis
|
homeostasis/metabolism
• lungs of some MERS-CoV infected mice show alveolar edema
|
nervous system
• brains of MERS-CoV infected mice show perivascular cuffing after 2 dpi
|
• degenerating neurons of MERS-CoV infected mice sometimes have basophilic cytoplasmic inclusions
|
• brains of MERS-CoV infected mice show cellular degeneration and debris after 2 dpi
• MERS-CoV-induced neuronal lesions are most severe in the thalamus and brain stem
|
renal/urinary system
• MERS-CoV-infected mice show scattered-to-patchy tubular injury, including tubular dilation, cell sloughing/debris, and cellular necrosis late in the course of infection
|
digestive/alimentary system
• intragastrically MERS-CoV incoculated mice show increased sloughing of the surface epithelium
|
• the small intestine of intragastrically MERS-CoV incoculated mice shows deteriorating inflammation and epithelial degeneration
• mice treated with pantoprazole (to improve viability of MERS-CoV in the stomach) prior to MERS-CoV intragastrical inoculation show more extensive and prominent pathology in the small intestine
|
• intragastrically MERS-CoV incoculated mice show broadening of the intestinal villi
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
Middle East respiratory syndrome | DOID:0080642 | J:286231 , J:285467 |